Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

被引：56

作者：

Yhim, Ho-Young

Lee, Na-Ri

Song, Eun-Kee

Yim, Chang-Yeol

Jeon, So Yeon

Shin, Seunghwan ^{[2
]}

Kim, Jeong-A ^{[2
]}

Kim, Hee Sun ^{[3
]}

Cho, Eun Hae ^{[4
]}

Kwak, Jae-Yong ^{[1
]}

机构：

[1] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Adv Res Canc Ctr, Jeonju 561712, South Korea

[2] Catholic Univ Korea, Coll Med, Div Hematol, Dept Internal Med, Seoul, South Korea

[3] Woosuk Univ, Dept Nursing, Wonju, South Korea

[4] Green Cross Reference Lab, Yongin, South Korea

来源：

LEUKEMIA RESEARCH | 2012年 / 36卷 / 06期

关键词：

Chronic myeloid leukemia; Complete molecular response; Imatinib mesylate; Real-time quantitative polymerase chain reaction; CHRONIC MYELOGENOUS LEUKEMIA; REMISSION; RISK; HALF; CML;

D O I：

10.1016/j.leukres.2012.02.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：689 / 693

页数：5

共 21 条

[1] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[2] BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria [J].

Branford, Susan ;

Seymour, John F. ;

Grigg, Andrew ;

Arthur, Chris ;

Rudzki, Zbigniew ;

Lynch, Kevin ;

Hughes, Timothy .

CLINICAL CANCER RESEARCH, 2007, 13 (23) :7080-7085

[3] Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate [J].

Cortes, J ;

Talpaz, M ;

O'Brien, S ;

Jones, D ;

Luthra, R ;

Shan, J ;

Giles, F ;

Faderl, S ;

Verstovsek, S ;

Garcia-Manero, G ;

Rios, MB ;

Kantarjian, H .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3425-3432

[4] To the editor: Discontinuation of imatinib therapy after achieving a molecular response [J].

Cortes, J ;

O'Brien, S ;

Kantarjian, H .

BLOOD, 2004, 104 (07) :2204-2205

[5] HEMATOLOGY Curing CML with imatinib-a dream come true? [J].

Deininger, Michael .

NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (03) :127-128

[6] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[7] Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients [J].

Guo, JQ ;

Lin, H ;

Kantarjian, H ;

Talpaz, M ;

Champlin, R ;

Andreeff, M ;

Glassman, A ;

Arlinghaus, RB .

LEUKEMIA, 2002, 16 (12) :2447-2453

[8] Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) [J].

Hughes, Timothy P. ;

Hochhaus, Andreas ;

Branford, Susan ;

Mueller, Martin C. ;

Kaeda, Jaspal S. ;

Foroni, Letizia ;

Druker, Brian J. ;

Guilhot, Francois ;

Larson, Richard A. ;

O'Brien, Stephen G. ;

Rudoltz, Marc S. ;

Mone, Manisha ;

Wehrle, Elisabeth ;

Modur, Vijay ;

Goldman, John M. ;

Radich, Jerald P. .

BLOOD, 2010, 116 (19) :3758-3765

[9] The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors [J].

Jabbour, Elias ;

Kantarjian, Hagop ;

O'Brien, Susan ;

Shan, Jenny ;

Quintas-Cardama, Alfonso ;

Faderl, Stefan ;

Garcia-Manero, Guillermo ;

Ravandi, Farhad ;

Rios, Mary Beth ;

Cortes, Jorge .

BLOOD, 2011, 118 (17) :4541-4546

[10] Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia - Need for new response definitions? [J].

Kantarjian, Hagop ;

O'Brien, Susan ;

Shan, Jianqin ;

Huang, Xuelin ;

Garcia-Manero, Guillermo ;

Faderl, Stefan ;

Ravandi-Kashani, Farhad ;

Verstovsek, Srdan ;

Rios, Mary Beth ;

Cortes, Jorge .

CANCER, 2008, 112 (04) :837-845

← 1 2 3 →